Pharmaceutical Companies Worldwide

ABO Holdings, Inc is a US-based blood plasma collection and supply company located in Irvine, California. We specialize in sourcing medical-grade source plasma for biotherapeutic pharmaceutical clients, playing a vital role in the production of life-saving injectable patient therapies.

At ABO Holdings, we operate a network of plasma donation centers across the United States, including New Jersey, Texas, California, Utah, and more. Our dedicated team guides donors through a simple and rewarding donation process, ensuring the highest quality plasma for our pharmaceutical partners.

What sets ABO Holdings apart is our commitment to providing a seamless and reliable supply chain for critical plasma components. We prioritize donor safety and satisfaction, fostering a community of individuals making a tangible difference in healthcare. We are proud to contribute to advancements in patient care through the collection and distribution of this essential resource.

Founded in 2020, ABO Holdings has rapidly grown to become a trusted partner within the biopharmaceutical industry, consistently meeting the demanding needs of our clients. We are dedicated to innovation and expanding our reach to further support the development of groundbreaking therapies.

Contract Packaging Resources, Inc is a leading pharmaceutical packaging solutions provider based in Greensboro, North Carolina. We specialize in providing comprehensive packaging services to the pharmaceutical, Rx, OTC, dietary supplement, and animal health industries.

CPR assists businesses with critical packaging needs, including RX/OTC bottling, blistering (thermoform/cold-form), cartoning, physician samples, kitting, unit-dose packaging, clinical trials, stability packaging, and medical kits.

As an FDA, DEA, and state-licensed facility (NC and FL), CPR ensures the highest standards of quality and compliance. We are a cGMP compliant partner dedicated to delivering exceptional service and tailored packaging solutions to meet the unique demands of the pharmaceutical market.

Founded in 1997, CPR has grown to serve a diverse client base, offering expertise in RF sealing, labeling, stretch-carding, and walleting. We are committed to supporting our clients’ success through reliable and efficient packaging services.

Steroids Drugs is an Orlando, Florida-based e-commerce specialist dedicated to providing a comprehensive selection of anabolic steroids, oral steroids, and performance-enhancing supplements. We cater to athletes and fitness enthusiasts seeking to optimize their results safely and effectively.

Our mission is to empower individuals to achieve their fitness goals by offering high-quality products and expert guidance. We specialize in sourcing from reputable manufacturers and ensuring discreet and secure shipping for all our customers.

Steroid Drugs distinguishes itself through its commitment to uncompromising quality, competitive pricing, and exceptional customer service. We provide detailed product information, fast delivery, and a secure platform for your purchases. We prioritize your safety and success, offering comprehensive resources and expert advice to help you make informed decisions.

Since 2017, we've been serving the bodybuilding and fitness community with a wide range of products, including Test Prop, Trenbolone, Anavar, and Post Cycle Therapy (PCT) options. We are committed to providing a safe and reliable source for performance-enhancing supplements. Steroids Drugs – Your Partner in Achieving Peak Performance.

Reata Pharmaceuticals is a Plano, Texas-based biopharmaceutical company dedicated to developing and commercializing innovative medicines for life-threatening diseases.

We focus on addressing significant unmet medical needs in areas such as Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Friedreich’s Ataxia, Kidney Disease, Lupus, Multiple Sclerosis, Postpartum Depression, and Spinal Muscular Atrophy.

Reata’s approach centers on leveraging its deep expertise in antibody technology and drug development to create targeted therapies that improve patient outcomes and transform the lives of individuals affected by these challenging conditions.

Following its acquisition by Biogen, Reata continues to build upon its legacy of scientific innovation and commitment to advancing medicine.

Lumicera Health Services is a leading specialty pharmacy provider based in Madison, Wisconsin, dedicated to optimizing patient well-being through innovative care solutions.

We specialize in delivering comprehensive specialty pharmacy services, including medication delivery, treatment consultation, and patient support, ensuring patients receive the personalized attention they need to manage complex conditions.

Lumicera distinguishes itself by combining clinical expertise with a patient-centric approach, offering unparalleled support to patients, prescribers, and pharmaceutical manufacturers. Our commitment to transparency and stewardship, coupled with our URAC accreditation, underscores our dedication to elevating the standard of care in specialty pharmacy.

As a division of Navitus Health Solutions, we leverage our national network and strategic partnerships to provide seamless access to resources and expertise, ultimately improving health outcomes for our patients and their communities.

Cogneta is a leading pharmacy program management provider based in Plano, Texas, specializing in comprehensive solutions for self-funded payers, TPAs, and benefits brokers.

We offer a complete, integrated approach to pharmacy benefits management, combining clinical advisory services, robust reporting and analytics, and proactive PBM vendor management. Our goal is to simplify pharmacy program administration and drive significant cost savings for our clients.

Cogneta’s expertise in areas such as pharmacy benefits consulting, self-insured payer pharmacy benefits, and TPA pharmacy benefits support, allows us to deliver tailored strategies that optimize performance and improve patient outcomes. We are committed to providing exceptional service and building long-term partnerships based on trust and results. Cogneta helps organizations navigate the complexities of the pharmacy landscape with confidence.

KNF Clean Room Products is a New Jersey-based manufacturer of clean and ultraclean films and bags, specializing in custom solutions for a variety of industries.

For over 50 years, KNF Clean Room Products has been dedicated to providing high-quality flexible packaging materials, including sterilized bags, barrier bags, and anti-static films. We cater to demanding sectors such as food processing, pharmaceuticals, and aerospace, ensuring product integrity and safety.

Our commitment to quality is underscored by our ISO-certified facilities and rigorous cleanroom standards. We offer a comprehensive range of nylon and polyethylene films, alongside custom packaging solutions tailored to your specific needs. We pride ourselves on reliable delivery and expert support, making us a trusted partner for businesses seeking superior packaging performance. Nylon Bags, Anti-Static Bags, and Moisture Resistant Bags are among our core offerings.

Tandem Labs is a leading bioanalytical service provider based in Salt Lake City, Utah.

We specialize in supporting the development of small and large molecules, offering a comprehensive suite of services from discovery through clinical studies.

Tandem Labs differentiates itself through scientific expertise, responsive project management, and a commitment to shortening development timelines for our clients – including biopharmaceutical companies, government agencies, and managed care organizations. As part of Covance, we leverage decades of experience to deliver innovative solutions and accelerate drug development.

With a strong regulatory history and a team of experienced scientists, we are dedicated to helping our partners bring life-changing therapies to market.

ASTA Research Laboratories is a leading pharmaceutical manufacturer and marketing company based in Lahore, Pakistan, specializing in the development and distribution of high-quality tablets, capsules, and injections.

We serve a broad range of healthcare professionals and patients across Pakistan, focusing on key therapeutic areas including orthopaedics, paediatrics, gynaecology, and nutraceuticals. Our commitment is to provide effective and reliable medications, addressing critical health needs with a focus on patient well-being.

ASTA Research Laboratories distinguishes itself through its established history, operational marketing team of over 100 professionals, and adherence to rigorous medical ethics and GPP standards. We are dedicated to fostering a culture of equal opportunity and continuous growth for our employees, driving innovation and expanding our product portfolio to meet evolving healthcare demands. Our flagship product, ASTADOL (Tramadol+ Paracetamol), exemplifies our dedication to quality and efficacy.

Restore Health is a leading personalized medicine pharmacy provider based in Madison, Wisconsin, serving healthcare professionals and patients across the United States.

For over four decades – since 1982 – Restore Health has been dedicated to providing high-quality, customized pharmaceutical solutions. Initially focused on women’s health compounding, we’ve expanded our offerings to encompass a comprehensive range of bioidentical hormones, specialty pharmacy services, and laboratory testing for both men and women.

We specialize in compounding, laboratory services, and clinical support, catering to the evolving needs of healthcare providers and patients seeking personalized treatment options. Our commitment to quality and patient care has established us as a trusted partner in the healthcare industry. We are proud to be recognized as one of the fastest-growing companies in the US, having ranked 36th on the Inc. 500’s fastest growing company list in 2014.

Kaiser Pharmaceutical Co is a leading Traditional Chinese Medicine (TCM) manufacturer and supplier based in Tainan, Taiwan.

We specialize in the research, development, and production of high-quality herbal extracts and Chinese patent medicines, catering to both domestic and international markets.

Kaiser Pharmaceutical distinguishes itself through a rigorous commitment to quality, evidenced by our PIC/S GMP and USDA-NOP certifications, ensuring the safety, efficacy, and purity of our products. We utilize advanced manufacturing techniques and adhere to strict Good Manufacturing Practice (GMP) guidelines, guaranteeing consistent quality and delivering the essence of TCM worldwide. Our ISO 9001 and ISO 17025 accreditations further demonstrate our dedication to excellence. Traditional Chinese Medicine, Herbal Extracts, Chinese Patent Medicine

H & Care Incorp is one of the best PCD pharma franchise company with pharmaceutical segments covering antibiotics, cardiovascular medicines, diabetic medicines, ortho medicines, derma medicines and general range medicines. The company holds GMP certifications, is ISO 9001:2015 certified, and has DCGI and FSSAI certifications. Guided by Mr. Munish Goyal and Mrs. Luvlish Goyal with expertise from reputable pharma companies. We supply and market a complete range of GMP-certified Pharmaceutical Formulations, Herbal Products and Supplements, working with 600+ associates across PAN India.

Divine Medicines is an online pharmacy in Lahore that makes it simple to buy medicines online. We serve families across Lahore with medicine home delivery, offering more than 4,500 genuine medicines, vitamins, baby care and personal care products from trusted brands. Prescription medicines are supplied against a valid prescription. We take orders from 8am to 11pm, seven days a week.

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

AMPLY Discovery is a drug and nutraceutical discovery company based in Northern Ireland. A spin-out company from Queen's University Belfast, we use machine learning and AI to discover new therapeutic molecules for hard-to-treat diseases. This includes developing new drugs to replace conventional antibiotics and help tackle AMR. Our discovery platform is designed to mine vast biological datasets in silico and validate hundreds of hits in vitro.

We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.

We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

Our mission is to create a comprehensive, patient-centric ecosystem that empowers individuals and healthcare professionals alike through a unique digital health platform to bring more quality of life for everyone.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

Abzena is the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules with headquarters in San Diego, CA and additional centres of excellence in Bristol, PA and Cambridge, UK. Abzena has extensive experience in developing Biologics and Bioconjugates, and provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. Forward-thinking and committed, Abzena finds the best solutions and uses the right technologies to design, develop and manufacture products to ensure we get vital medicines to patients. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors and Biospring Partners.

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development. Imprint: https://iomx.com/imprint

Pharmacy2U is the UK's first and largest online pharmacy. We're a market leader in the pharmacy world, helping over 750,000 patients in England manage their NHS repeat prescriptions from request through to delivery. For over 20 years, we have used cutting-edge technology alongside our UK-based pharmacists, dispensing specialists, and customer care advisers to help improve the lives of patients. Our Leeds and Leicester -based dispensing facilities distribute over 1 million medication items to patients across England every month. KPMG’s Customer Excellence report recently revealed Pharmacy2U is the UK’s number one brand for experience and value, based on a survey of over 10,000 UK consumers. This accolade cements our position as the nation’s go-to online pharmacy and keeps us committed to further broadening our healthcare offering. Our goal is to make simple and convenient healthcare accessible to all. As well as our repeat prescriptions service, patients can also access: - A one-stop online healthcare shop featuring over 4,000 products - Confidential online GP consultations for a range of conditions - Enhanced pharmacy services such as the NHS New Medicine Service We're an ambitious company with big plans and we're looking for talented individuals to join our team and help us to continue excelling in our field. Our CEO Kevin Heath says, “come and join a team that truly lives by our company values of putting the patient at the heart of everything we do”. Want to help shape the future of online healthcare in the UK? Discover our latest vacancies today.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

AceCann is a Portuguese medical cannabis company that has put together a strong management team with diversified and complementary backgrounds that we trust will make a difference in the global market. The team combines +60 years of healthcare/pharma experience, +11 years operating medical cannabis companies in Canada and Portugal, and +14 years operating with technology/data business. AceCann’s scope of action is: •Organic Medical Cannabis Cultivation & Extraction Facility - building a cost-efficient, scalable and superior quality organic indoor cultivation and extraction facility near Lisbon leveraging on the experience from one or our shareholders •Therapeutics Research & Development - focused on the development of new medical delivery forms for cannabis, joining efforts with local and international universities With a team accustomed to highly volatile environments, AceCann is setting up a flexible structure to learn from a market in constant evolution & change, capable of making fast decisions to scale according to market demands & needs

Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease. We are inspired by some of the most pressing public health challenges of our time to help advance innovation with the potential to improve treatment options and outcomes for patients. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers, and broader impacted communities. In this context we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and awareness, and advocacy for important policies that support equitable access to quality treatment. Headquartered in Dublin, Ireland, we have an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines

Allero Therapeutics is a Dutch, venture-backed, biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates. We are hiring! Check our career website: https://jobs.lever.co/aqemia.com Blog Posts on: https://medium.com/aqemia

Ascent Clinical Research Solutions helps pharmaceutical companies transform their ideas and concepts into successful products. We are a highly focused team of professionals who understand how to prepare, manage and conduct clinical trials. Our core activities include but are not limited to Phase I-II-III, post-marketing observation programs for world’s leading biopharmaceutical companies & Bioequivalence studies in numerous patient populations, conducted in our own dedicated hospital-based clinical pharmacology units and under multicenter set-ups in Russia and Georgia.

BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalised medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in the healthcare setting into actionable insights. With our innovative technology we are creating a patient centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonise, and manage, from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed a Global Data Partner Network, BCRQUEST.com, which allows access to high-quality real-world data. This rapidly growing network has a footprint across many sites, including networks of major hospitals, covering 20 countries in five continents, providing standard of care data for over 23 million patients. Our platforms seamlessly facilitate access to highly enriched data for pharmaceutical research and development. Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London and Boston. For more information, please visit www.bcplatforms.com.

Biocellvia is a french company developing Intelligent Image Analysis solutions for pharmaceutical industry (Big Pharma, Biotechs, CRO) and academic communities involved in R&D. We have developed digital image analysis solutions, that enable to evaluate fully-automatically the level of efficacy of your lead molecules thanks to histological slides (in vitro, ex vivo, biopsies) in various pathologies such as: - Gastrointestinal (NASH, Liver fibrosis) - Respiratory (IPF, COPD, PAH) We provide image analysis as a service. Our technology evaluates your molecules with more accuracy, more reliability, more rapidity and less variability than traditional scoring methods. A full study (about 200 images) is performed in only a couple of days. http://biocellvia.com http://linkedin.com/company/biocellvia

New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine.

EpiEndo Pharmaceuticals is an Icelandic clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract and skin. EpiEndo was founded in 2014.

Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.

Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. Anjarium’s versatile platform builds on novel therapeutic payloads and delivery technologies, with the aim to unlock the full potential of gene therapy.

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York. *Reach out to us* Email: hello@benevolent.ai Careers: Careers@benevolent.ai Twitter: @benevolent_ai Website: benevolent.com

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry. C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m. The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery

To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.

CV6 Therapeutics is an early stage drug development company focused on the discovery, development and commercialization of novel combination therapies for the treatment of cancer. For further investment questions or opportunities please contact: information@cv6t.com

Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.

Datacapt provides a global, easy-to-use, flexible, and powerful electronic data capture platform (EDC) for on-site, hybrid, or decentralized Clinical Trials. We allow Sponsors, CROs, and Subjects to work together in a simple way with a huge engagement. Our Platform brings simplicity, efficiency, and quality to the collection of clinical data. Datacapt is making the promise to simplify and accelerate clinical tests with innovative solutions. Simplify the management of your trial with the Datacapt platform. Developed with specialists and experts, our platform is flexible and adapted to your studies. We offer a modular platform with everything in one place to design and manage all your trials (EDC, eCRF, ePRO/eCOA/eDiary, eConsent, eConsult, and Data Analysis…). - Significantly reduced time spent on study setup and management (Simple and flexible eCRF, ePRO, eConsent creation) - Real-time monitoring - Allows reducing manual tasks, data retranscription, and zero time spent on data export - Fast and easy implementation - Secure and 100% Compliant

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

Fab’entech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

ICONOVO AB is developing proprietary inhalation products for licensing. We have long experience and track record in the development of dry powder inhalers and offer a comprehensive range of devices to our clients. Our selection of device concepts for dry powder inhalation include a reservoir inhaler, a pre-metered inhaler, a capsule based inhaler and a single dose disposable inhaler. We can also provide formulation development, performance testing, documentation and a complete supply-chain.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).